This popular event fills to capacity every year, so please reserve your space by Wednesday, August 23, 2017.

Call 1-877-DFCI-BWH.

youhaveus.org
You are invited to attend the

19th Annual Symposium on Prostate Cancer

Issues and Options about Detection and Treatment of Prostate Cancer

Wednesday, September 6, 2017

BOSTON MARRIOTT NEWTON
2345 Commonwealth Avenue, Newton, MA

6 – 8 p.m. – Presentations, Questions, Discussion
8 – 9 p.m. – Reception and Conversation with Speakers

Specialists at Dana-Farber/Brigham and Women’s Cancer Center invite you to join them as they present the latest information on prostate cancer. At the 19th Annual Symposium on Prostate Cancer, our team of pioneering, nationally and internationally prominent specialists will discuss the following:

- Practice changing advances in the management and detection of prostate cancer
- Controversies about early detection and screening using PSA and other novel biomarkers
- Traditional surgical and radiation approaches, as well as newer less invasive techniques and procedures used in the management of prostate cancer
- Staging: What treatment is necessary?
- Long term follow-up and survivorship
- Novel treatments for advanced prostate cancer
- Management of the possible side effects of commonly used treatments for prostate cancer

You will have the opportunity to meet the panelists and ask questions about the latest advances in prostate cancer research and treatment.

This popular event fills to capacity every year, so please reserve your space by Wednesday, August 23, 2017.

Call 1-877-DFCI-BWH

youhaveus.org

Our Featured Speakers:

Radiation Oncologist Anthony V. D’Amico, MD, PhD
Dr. Anthony V. D’Amico will present advances over the past year from clinical trials in the management of prostate cancer. Dr. D’Amico is Chief of the Genitourinary Radiation Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center. He has been honored with the Eleanor Theresa Walters Distinguished Chair of Radiation Oncology at Brigham and Women’s Hospital where he provides mentorship to medical students and physicians in training. Also, he is the principal investigator on several federally-funded initiatives. These include examining the efficacy of future novel treatment approaches to prostate cancer through carefully designed international clinical trials run through collaborations he has made with prostate cancer experts in Canada, Europe, Australia, and New Zealand. Dr. D’Amico was awarded the Harvard Medical School (HMS) distinction of the Arnold P. Gold Humanism in Medicine Award in 2012 and the HMS Faculty Mentoring and Teaching Award in 2014 and 2015.

Medical Oncologist Mary-Ellen Taplin, MD
Dr. Mary-Ellen Taplin is the Director of Clinical Research for the Lank Center for Genitourinary Oncology at Dana-Farber/Brigham and Women’s Cancer Center. She will present on recent advances in the treatment of advanced prostate cancer. She is an Associate Professor of Medicine at Harvard Medical School. Her research and clinical interests include prostate cancer, testis cancer, bladder cancer, kidney cancer, and hormones and chemotherapy.

Surgical Oncologist Adam S. Kibel, MD
Dr. Adam S. Kibel is Chief of Urologic Surgery at Dana-Farber/Brigham and Women’s Cancer Center and Brigham and Women’s Hospital and Professor of Surgery at Harvard Medical School. Dr. Kibel will provide an overview of prostate cancer treatments from surgery to active surveillance. His clinical practice focuses on minimally invasive and robotic approaches to urologic cancer and his research areas focus on identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches for aggressive disease, and improved imaging of patients with urologic malignancies. He has recently served on the National Cancer Institute (NCI) Genitourinary Clinical trials steering committee, the Society of Urologic Oncology (SUO) Board of Directors, and the NCCN Prostate Cancer Screening Committee.

Surgical Oncologist Jerome P. Richie, MD
Dr. Jerome P. Richie is a leading expert in the diagnosis and treatment of prostate cancer. Dr. Richie will provide an overview of prostate cancer, controversies about early detection and screening, growth patterns as they relate to Gleason sum and evaluation, and ways to determine the best treatment. He also will discuss how to weigh the benefits and potential side effects of surgery. He is Chief of Urologic Surgery (Emeritus) at Dana-Farber/Brigham and Women’s Cancer Center and Brigham and Women’s Hospital and is the Elliott C. Cutler Professor of Surgery at Harvard Medical School. Dr. Richie also is a past president of the Society of Urologic Oncology, the Society of University Urologists, and the American Board of Urology. He serves on the National Comprehensive Cancer Network (NCCN) Advisory Panel on Bladder Cancer.